(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
US bishops officially ban gender-affirming care at Catholic hospitals - 2Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- 3Former elite Australian soldier charged with Afghan war crimes
- 4Rick Steves Prefers Paying A Bit Extra For This Delectable Food When Dining In Spain
- 5Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- Could the Star of Bethlehem have actually been a comet?
- Top 10 Moving Style Architects of the Year
- Twins were the norm for our ancient primate ancestors − one baby at a time had evolutionary advantages
- Investigate These Retreats Well known With Seniors
- Which Film Has the Incomparable Melodic Score?
- Hungary's 'water guardian' farmers fight back against desertification
- The Most Vital Crossroads in Olympic History
- A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
